PDF(Pubmed)
Abstract：
Fat malabsorption is central to the pathophysiology of short bowel syndrome (SBS). It occurs in patients with insufficient intestinal surface area and/or function to maintain metabolic and growth demands. Rapid intestinal transit and impaired bile acid recycling further contribute to fat malabsorption. A significant portion of patients require parenteral nutrition (PN) for their survival but may develop sepsis and liver dysfunction as a result. Despite advancements in the treatment of SBS, fat malabsorption remains a chronic issue for this vulnerable patient population. Peer-reviewed literature was assessed on the topic of fat malabsorption in SBS. Current management of patients with SBS involves dietary considerations, PN management, antidiarrheals, glucagon-like peptide 2 agonists, and multidisciplinary teams. Clinical trials have focused on improving intestinal fat absorption by facilitating fat digestion with pancreatic enzymes. Targeting fat malabsorption in SBS is a potential pathway to improving lifestyle and reducing morbidity and mortality in this rare disease.
摘要：
脂肪吸收不良是短肠综合征（SBS）病理生理学的核心。它发生在肠表面积和/或功能不足以维持代谢和生长需求的患者中。快速的肠道运输和胆汁酸再循环受损进一步导致脂肪吸收不良。很大一部分患者需要肠胃外营养（PN）才能生存，但结果可能会发展为败血症和肝功能障碍。尽管SBS的治疗取得了进展，对于这个脆弱的患者群体来说，脂肪吸收不良仍然是一个长期问题。对SBS中脂肪吸收不良的主题进行了同行评审的文献评估。目前对SBS患者的管理涉及饮食方面的考虑，PN管理，止泻药,胰高血糖素样肽2激动剂，和多学科团队。临床试验的重点是通过用胰酶促进脂肪消化来改善肠道脂肪吸收。针对SBS中的脂肪吸收不良是改善这种罕见疾病的生活方式并降低发病率和死亡率的潜在途径。
